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Vinpocetine (ethyl-apovincaminate, Cavinton), a synthetic derivative of the
Vinca minor alkaloid vincamine, has been used now for decades for preven-
tion and treatment of cerebrovascular diseases predisposing to development
of dementia. Both vinpocetine and its main metabolite cis-apovincaminic acid
(cAVA) exert a neuroprotective type of action. Bilateral N-methyl-D-aspartate
(NMDA)-induced neurodegeneration in the entorhinal cortex of rat was used
as a dementia model to conﬁrm the neuroprotective action of these com-
pounds in vivo. NMDA-lesioned rats were treated 60 min before lesion and
throughout 3 postoperative days with a 10 mg/kg intraperitoneal dose of vin-
pocetine or cAVA. Behavioral tests started after termination of drug treatment
and consisted of novel object recognition, social discrimination, and sponta-
neous alternation in a Y-maze, and spatial learning in the Morris water maze.
At the end of behavioral testing brains were perfused with ﬁxative and the
size of the excitotoxic neuronal lesion and that of microglial activation around
the lesion were assayed quantitatively on brain sections immunostained for
neuron-speciﬁc nuclear protein (NeuN) and integrin CD11b, respectively. En-
torhinal NMDA lesions impaired recognition of novel objects and the new
social partner, and suppressed spontaneous alternation and spatial learning
performance in the Morris maze. Both vinpocetine and cAVA effectively at-
tenuated the behavioral deﬁcits, and signiﬁcantly decreased lesion size and
the region of microglia activation. Both lesion-induced attention deﬁcit and
learning disabilities were markedly alleviated by vinpocetine and cAVA. The
morphological ﬁndings corroborated the behavioral observations and indicated
reduced lesion size and microglia activation especially after vinpocetine treat-
ment which supports an in vivo neuroprotective mode of action of vinpocitine
and a less potent action of cAVA.
Vinpocetine (ethyl-apovincaminate, Cavinton) a syn-
thetic derivative of the Vinca minor alkaloid vincamine is
currently prescribed for the treatment of disorders arising
from cerebrovascular and cerebral neurodegenerative
diseases leading ultimately to dementia in the elderly.
Although the complex neuroprotective mechanism
underlying the therapeutic action of vinpocetine is
not yet fully clariﬁed several reports during the last
decade point to molecular targets of this drug which are
associated with its effects on voltage-dependent sodium
channels, glutamate receptors, voltage-operated calcium
channels, and calcium- and calmodulin-dependent cyclic
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guanosine monophosphate-phosphodiesterase. [1–4]
Vinpocetine may also act through the peripheral benzo-
diazepine receptors in the brain [5,6] which are highly
expressed in microglia but have also been identiﬁed in
neurons [7].
Neuroprotection in vivo by vinpocetine has been stud-
ied in a number of hypoxia-ischemia models (reviewed
by B¨ on¨ oczk et al. [3]). Several mechanisms have been
postulated to explain neuronal cell death in hypoxia, is-
chemia and chronic neurodegenerative diseases, includ-
ing excessive excitotoxic neurostimulation, calcium over-
load, oxidative stress, programmed cell death and brain
vascular deterioration [8]. However to date experimental
neurodegenerative models other than hypoxia-ischemia
have not yet been applied to explore the in vivo mode
of action of vinpocetine and its derivatives, but neuronal
overexcitation by glutamate, formation of free radicals,
chronic inﬂammation, or trauma may all contribute to
the neurodegenerative process. The aim of the present
study was to apply an in vivo glutamate-induced overex-
citation model to study the potential neuroprotective ac-
tion of vinpocetine.
In humans, vinpocetine is rapidly absorbed orally and
subject to an intense ﬁrst pass metabolic turnover during
which the larger part of the substance is hydrolyzed into
its active metabolite, cis-apovincaminic acid (cAVA) [9–
11]. Therefore, the question came up whether this main
metabolite plays an active role in the neuroprotective ac-
tion of vinpocetine. Consequently we compared the pu-
tative neuroprotective potential of vinpocetine as well as
that of cAVA.
For the current study we chose for N-methyl-D-
aspartate (NMDA)-induced excitotoxic lesioning of the
entorhinal cortex in rats. Applying this model a clear
deﬁcit in the Morris maze spatial learning test could
be obtained as a result of hippocampal dysfunction due
to the partial disruption of the massive perforant path-
way connection of the entorhinal cortex to the den-
tate gyrus of the hippocampus [12–14]. Degeneration of
the perforant path results in a shrinking of the molec-
ular layer of the dentate gyrus [15,16]. In essentially
all cases of Alzheimer’s disease the deranged connectiv-
ity between the entorhinal cortex and the hippocam-
pus is the initial event leading to short-term memory
disturbance and attention deﬁcit [17–19]. Therefore, in
our animal model in addition to spatial learning, we
also assessed attention deﬁcits that resulted from the
NMDA-induced entorhinal lesion. Drug effects were es-
tablished with a preselected optimal dose of 10 mg/kg
of vinpocetine and of its metabolite cAVA applied
both pre- and postsurgery. Behavioral analysis was fol-
lowed by a postmortem neuropathology analysis in
which we quantiﬁed the size of neuronal lesion in
the entorhinal cortex and the accompanying microglia
activation.
Experimental Procedures
Animals
Male Harlan-Wistar rats weighing 300–400g outbred in
our laboratory were group housed with three animals
per cage with free access to food and water at a standard
temperature of 23 ± 1◦C in a light-controlled room (light
on from 07:00 a.m. to 07:00 p.m.). Behavioral tests were
performed during the light phase between 9:00 a.m. and
3:00 p.m. The animal experiments were carried out in ac-
cordance with the European Community Council Direc-
tive for the care and use of laboratory animals and were
approved by the Scientiﬁc Ethical Committee on Animal
Experimentation, Animal Health Care Station Budapest
1135, Lehel u. 43–47 (1327/003/Fov/2005).
Drug Treatments
Vinpocetine (cis:-ethyl-apovincaminate) and cAVA were
supplied by Gedeon Richter Company (Budapest,
Hungary). The 10 mg/kg dose was selected for both com-
pounds as optimal dose based on previous in vivo stud-
ies in our laboratories. Rats were divided into seven
groups: intact (9); sham-lesioned vehicle-injected control
(12); sham-lesioned vinpocetine-treated (6); sham-
lesioned cAVA-treated (6); NMDA-lesioned and vehicle-
treated (14); NMDA-lesioned and vinpocetine-treated
(8); and NMDA-lesioned and cAVA-treated (8). One an-
imal from the 7th group (NMDA + cAVA) was dis-
carded because of health problems and severe loss of body
weight. Drug-treated rats received either 10 mg/kg vin-
pocetine or 10 mg/kg cAVA intraperitoneally 60 min be-
fore and 90 min after surgery, and two injections per
day for three consecutive days (altogether 8 injections)
in 1 mL/kg physiological saline solution containing 0.1%
Tween 80 and ascorbic acid. Sham-lesioned and NMDA-
lesioned controls received the vehicle solution alone.
NMDA-lesion
Excitotoxic lesioning of the entorhinal cortex was car-
ried out bilaterally. Rats were anesthetized with sodium
pentobarbital by intraperitoneal injection and positioned
in a Narishige stereotactic frame. With a Hamilton sy-
ringe of 10 μL, 30nmol N-methyl-D,L-aspartate (NMDA,
Sigma, St. Louis) dissolved in phosphate-buffered saline
pH7.4 (PBS) was injected bilaterally into each of three
different locations of the entorhinal cortex. The volume
of each injection was 0.5μL and the infusion time was
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0.1μL/min. At the end of each injection the needle was
left in place for another 3min to prevent loss of the toxin
in the needle track. Altogether six injections (six times
30 nmol NMDA) were applied to the entorhinal cortices.
The stereotaxic coordinates measured from Bregma ac-
cording to the atlas of Paxinos and Watson [20] were:
craniocaudal −6.4, −6.7, −6.8; lateral 4.0, 2.4, 3.5;
dorsoventral 8.2, 7.8, 7.4. The injection locations were
approached at an angle of 15◦. Sham-lesioned animals
received PBS solution alone. Animals were allowed to re-
cover after surgery for 3 days during which period they
were treated either with vinpocetine or with cAVA as de-
scribed above before the behavioral testing was started.
Behavioral Tests
All behavioral tests were performed blindly and the indi-
vidual animals from the different groups and cages were
selected randomly for the testing. The experimental ani-
mals could not see the experimenter, because the test are-
nas were observed through an optical camera positioned
1.5 m above the arenas, which also allowed to carry out
video recording. The behavioral tests started in the morn-
ing of the 5th postoperative day, that is, one and a half
days after the last drug injection.
Novel Object Recognition
On postsurgery day 5 novel object recognition was tested
in a habituated open ﬁeld arena according to Myhrer
et al. [21]. During the ﬁrst session two identical objects
were placed into the arena at an equal distance from the
wall in an asymmetric position with respect to the center
of the arena. These objects became familiar objects during
the 5 min test period. After a 2 hours intersession interval
spent in the home-cage the rats were replaced into the
open-ﬁeld arena for the 2nd session that lasted another
5 min. During the second session one of the familiar ob-
jects was replaced by a novel object. The time (sec) spent
on visiting the objects were recorded. The total dura-
tion of visits towards both objects served as general ex-
ploratory activity, while for discriminating the novel from
the familiar object the following calculation was applied:
Novelobjectrecognition(%) =
durationofvisitstonovelobject
durationofvisitstonovel + familiarobjects
× 100
Fifty percent represented no discrimination or no recog-
nition of novelty.
Social Discrimination Test
The experiment was performed 6 days after surgery ac-
cording to description of Von Frijtag et al. [22] in a
70 cm rectangular arena surrounded by a 35 cm high
wall. The ﬂoor was covered with sawdust, which was
mixed after each test. The arena was illuminated from
a height of 120 cm by a red bulb of 40W. After 2h ha-
bituation in the observation room the test animal was al-
lowed to explore the arena for 3 min. After that a juvenile
male partner rat was placed into the arena for 5 additional
min (learning phase). During the inter-trial interval, an-
imals were replaced into their home cage for 7 min. The
retrieval trial was started by replacing the test rat into
the arena upon which the familiar rat was introduced to-
gether with a new juvenile male from the same cage. So-
cial interactions (snifﬁng, grooming, following) towards
the familiar and the novel juvenile rat, respectively, were
recorded for 3 min. Data were expressed as frequency
(in scores per 3 min) or time (in seconds) of social inter-
actions towards the new partner divided by interactions
towards the familiar partner. In case of attention and/or
memory deﬁcits, test rats were unable to differentiate be-
tween the familiar and the new partner, and the ratio was
around 1.
Spontaneous Alternation
Attention and working memory was assessed on the sev-
enth postoperative day in the course of spontaneous al-
ternation in a Y-maze described earlier [23]. The maze
was made from black plastic material with sawdust on the
ﬂoor. Sawdust was mixed after each test for eliminating
odor prints. The arms were 50 cm long, 30 cm high, 10 cm
wide and converged at a 120◦ angle. Each rat was placed
at the center of the maze and allowed to move freely for
5 min. The number of arm entries was recorded. Alterna-
tion was deﬁned as entering the arm different from the
two previous arms entered and was expressed as percent
of total entries.
Spatial Learning in a Morris Water Maze
The test procedure started at the 8th postoperative day
and continued for another 4 days, that is, ﬁve daily ses-
sions were performed. The Morris water maze test [24]
was carried out in a black round water tank (diameter
153cm, height 63cm) ﬁlled to a depth of 53 cm with wa-
ter of 26 ± 1◦C. The tank was divided into four (imagi-
nary) quadrants. A black hidden platform with a diame-
ter of 8 cm was submerged in the center of one quadrant
1.5cm below the water surface. Four different starting po-
sitions were equally spaced around the perimeter of the
tank. The animals had to learn to ﬁnd the hidden plat-
form orientating by different visual cues placed on the
wall of the experimental chamber. The order of start-
ing positions varied randomly between sessions, but was
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constant within a daily session. Four trials were given per
daily session. Rats were placed into the water at a starting
position facing the wall of the tank. Each trial lasted until
the rats found the platform. If the platform was not found
during 90 sec, the operator led the animal to it. Rats spent
30 sec on the platform at the end of each trial. Latency
time to ﬁnd the platform was measured during each trial.
Latency to ﬁnd the platform at the ﬁrst trial was consid-
ered as a measure of reference memory and computed
separately. Spatial learning performance was reﬂected by
the mean escape latency calculated by averaging all four
trials.
Brain Tissue Analysis
Brain Fixation and Sectioning
Brain ﬁxation was carried out at postoperative days 13 by
transcardial perfusion of heparinized PBS pH7.4 followed
by 4% paraformaldehyde (Sigma-Aldrich, Hungary) so-
lution containing 0.05% glutaraldehyde (Sigma-Aldrich,
Hungary) in 0.1M phosphate buffer (PB, pH7.4) after ad-
equate deep pentobarbital anesthesia. After postﬁxation
of the brains for 48 h in the same ﬁxative the brains
were stored in 0.1M PB containing 0.1% Na-azide un-
til histological examinations. For histological processing
the brains were cryoprotected by storage in PB containing
30% sucrose and sectioned in a Leica cryostat microtome
at a thickness of 30 μm to obtain horizontal sections of
the entorhinal cortex and ventral hippocampus in sham-
operated control and NMDA-lesioned animal.
Immunocytochemistry
Identiﬁcation of neurons and activated microglia. Mouse anti-
neuron-speciﬁc nuclear protein (Neuronal Nuclei, NeuN,
MAB377, Chemicon) antibody recognizes most neuronal
types in the central nervous system but not glial cells.
Therefore, it is an adequate tool for outlining the precise
area of loss of neurons in an anatomical structure after
different lesions. This staining, therefore, allows a quan-
titative measurement of lesion size, which reﬂects the
area of lost neurons. The antibody against the integrin,
CD11b, was selected to label activated microglia. In the
control brain baseline level activity of microglia is mini-
mal and hardly visible after immunocytochemical stain-
ing. Microglia activation becomes markedly enhanced in
and around the lesion or degeneration of the nervous tis-
sue. Mouse anti-rat CD11b (MAB1405Z, Chemicon), as
primary antibody was used in the microglia immunoas-
say. Both NeuN and CD11b antibodies were applied in a
dilution rate of 1:1000. The biotinylated secondary horse
anti-mouse antibody and the Vectastain ABC kit were ob-
tained from Vector Labs (CA, USA) and used in 1:500
dilution rate. The staining was completed with nickel-
enhanced diaminobenzidine (DAB, 3,3’-diamino benzi-
dine, Sigma) reaction in the presence of H2O2.
The extent of neuronal loss and that of microglial acti-
vation around the lesion were manually delineated and
quantiﬁed with the Quantimet 600 (Leica, Cambridge,
UK) image analysis system. Three brain sections were an-
alyzed per animal and the results were averaged.
Statistical Analysis
Statistical comparisons between groups were conducted
using one-way ANOVA or two-way ANOVA with re-
peated measures on one factor, where appropriate. In
cases in which the overall ANOVA indicated signiﬁcant
effects, post hoc analysis was applied using Tukey HSD
test. All statistical analyses were done applying the Sta-
tistica 8.0 program. The statistical signiﬁcance was set at
P < 0.05. Means and standard errors of means (SEM) are
presented to demonstrate the results.
Results
Behavioral Analysis
Novel Object Recognition
NMDA-induced excitotoxic lesioning of the entorhinal
cortex markedly affected the recognition of a novel ob-
ject positioned in the habituated open ﬁeld (Fig. 1).
One-way ANOVA revealed a signiﬁcant treatment effect:
F6,55 = 5.63, P < 0.001. Post hoc Tukey test showed that
the NMDA-lesioned group performed inferior to sham
control (P < 0.01) and both vinpocetine and cAVA were
effective in preventing the attention deﬁcit (P < 0.05 and
P < 0.01 vs. NMDA control, respectively). Performances
of intact and sham-injected groups were not different.
The novel object recognition of the NMDA group was
also impaired against intact and both drug-treated sham
groups (not shown in the ﬁgure to avoid overcrowded
statistical presentations).
Social Discrimination
Similar to novel object recognition the social discrimina-
tion ability was also impaired by the lesion tested at post-
operative day 6 (Fig. 2). The frequency ratio of visiting
the new versus the familiar partner was different between
groups: F6.55 = 3.55, P < 0.01, so was the duration ratio:
F6.55 = 3.03, P < 0.02. Post hoc comparison of two groups
showed that the NMDA lesion decreased social recogni-
tion against sham control rats as shown in ﬁgure 2 (fre-
quency: P < 0.01, duration: P < 0.05). Furthermore the
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Figure 1 Attention ability of rats to recognize a novel object in a habit-
uated open-ﬁeld arena tested 5 days after surgery. The time spent with
explorationofthenovelobjectinpercentoftimespentwithexplorationof
both novel and familiar objects is shown. The 50% represents the chance
level. Animals with bilateral entorhinal lesion (NMDA) performed worse
than sham controls (∗∗P < 0.01) and treatments with vinpocetine (Vinp)
andcis-apovincaminicacid(cAVA)inadoseof10mg/kgi.p.preventedthis
deﬁcit (#P < 0.05 and ## P < 0.01 vs. NMDA group, respectively). The
numbers of animals per groups are showed inside the columns. Columns
represent means ± SEM.
lesion decreased social interaction compared with intact
animals (P < 0.01 and P < 0.05 for frequency and dura-
tion respectively); however, this statistical ﬁnding is not
depicted in the ﬁgure, because the sham control group is
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Figure 2 Socialdiscriminationperformanceexpressedasaratioofinter-
actionswiththenewvs.familiarpartnerstestedat6th postioperativeday.
Frequency and duration of social interactions after NMDA lesion against
shamcontrolswerereduced(∗∗P<0.01and∗P<0.05,respectively).Drug
treatments (vinpocetine and cAVA) attenuated the deﬁcit caused by the
lesion (#P < 0.05 vs. NMDA). The performances were comparable among
the intact and sham-lesioned groups with or without drug treatments.
Columns represent means ± SEM.
considered as the appropriate control. Both drugs attenu-
ated the effect of the NMDA lesion since the NMDA plus
drug-injected groups performed statistically similar as the
sham controls and intact groups. With respect to the du-
ration of interactions the NMDA+Vinp group differed
signiﬁcantly from the NMDA control group (P < 0.05,
Fig. 2).
Spontaneous Alternation
Spontaneous alternation in the Y maze was tested at post-
operative day 7 (Fig. 3). The performance of different
groups was evaluated by one-way ANOVA: F6,55 = 3.33,
P < 0.01. Post hoc Tukey test showed that NMDA lesions
signiﬁcantly impaired alternation (P < 0.01) against sham
controls, while both treatments (vinpocetine and cAVA)
attenuated the lesion effect. Drug-treated lesioned groups
did not differ from the sham control group. Vinpocetine-
treated lesioned animals performed better compared with
the NMDA-lesioned controls (P < 0.05).
Spatial Memory
Acquisition of spatial memory to ﬁnd the submerged plat-
form in the Morris water maze was tested throughout
ﬁve consecutive daily sessions. The spatial learning per-
formance of the seven groups is shown in ﬁgure 4. Es-
cape latency of the ﬁrst trials of each daily session was
separately evaluated and served as a measure of reference
memory (RM, Fig. 4A and B). The means of all four trials
per session was also calculated (Fig. 4 C and D). For a bet-
ter overview of the results the seven goups were divided
in two containing 4–4 groups: the sham-operated and
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Figure 3 SpontaneousalternationinpercentoftotalarmentriesintheY
maze 7 days following NMDA-induced excitotoxic lesion in the entorhinal
cortex. NMDA lesion decreased alternation (∗∗P < 0.01 vs. sham) and the
twodrugtreatments(vinpocetineandcAVA)provedtobepreventive,that
is, no differences were found against the sham and intact controls. The
difference between the NMDA+Vinp and NMDA groups was signiﬁcant
(#P < 0.05). Columns represent means ± SEM.
intact groups (two upper panels) and the NMDA-injected
groups and their sham-operated controls (two lower
panels).
The escape latency performed at the ﬁrst trial of ses-
sions while leaving out the ﬁrst session (Fig. 4A and B)
showed signiﬁcant effects of the group factor (F6,54 =
5.33, P < 0.001) and that of session factor with repeated
measures (F3,162 = 16.70, P < 0.001) without a signiﬁcant
group–session interaction. In the statistical evaluation of
the ﬁrst trials (RM) the session one was not included, as
mentioned above, because the very ﬁrst latency to ﬁnd
the platform is inﬂuenced mainly by chance and clearly
accidental. Evaluating means of daily trials (Fig. 4C and
D), including all ﬁve sessions, resulted in a similar pic-
ture (groups: F6,54 = 4.94, P < 0.001; sessions: F4,216 =
101.69, P < 0.001; no groups–sessions interaction) indi-
cating that there was a difference in the performance be-
tween groups and all groups showed learning.
In the next step of statistical analysis based on the two-
way ANOVA with repeated measures the differences be-
tween two groups was evaluated with the post hoc Tukey
test. For the evaluation of the ﬁrst trials (RM) in ses-
sions 2–5, the NMDA-lesioned group differed from sham-
controls (P < 0.05) and was also different from intact
controls (P < 0.005). NMDA-vinpocetine- as well as
NMDA-cAVA- treated groups were different from the
NMDA control group (P < 0.05 and P < 0.001, re-
spectively), but the two drug-treated groups were not
different from sham controls. No difference was found
between the control groups: intact; sham-lesioned; and
sham-lesioned treated either with vinpocetine or cAVA.
Similar picture emerged in evaluating learning perfor-
mance when the means of four trials were considered
(panels C and D). In this case including also session 1,
there was a signiﬁcantly impaired performance of the
NMDA group against sham control (P < 0.05) and also
against normal control groups (P < 0.005). The drug
treatments (vinpocetine and cAVA) prevented the deﬁcit
of lesioned animals: P < 0.05 and P < 0.001, respec-
tively, versus NMDA control. The performance of drug-
treated groups was not different from that of sham con-
trols. Furthermore, no difference was found between the
intact and sham-lesioned groups. Thus, either the ﬁrst tri-
als or the mean trials test evaluations clearly showed that
NMDA lesions in the entorhinal cortex decreased spatial
memory performance and both vinpocetine and cAVA
signiﬁcantly interfered with this deﬁcit.
The daily performance could also be analyzed sepa-
rately with one-way ANOVA. There were signiﬁcant dif-
ferences among groups shown on ﬁgure 4(B) and (D) at
session 4 and 5 testing latency of ﬁrst trials (P < 0.01
both) and at sessions 3, 4, and 5 testing mean perfor-
mances (P < 0.001, P < 0.02 and P < 0.001, respectively).
Post hoc Tukey test revealed further group differences de-
picted on the ﬁgure. Both for ﬁrst and mean trials, the
marked distinctions between the groups was only found
at the last two or three sessions.
Brain Tissue Analysis
Extent of Neuronal Lesion and Microglia Activation
in the Entorhinal Cortex
The different drug treatments signiﬁcantly reduced the
size of entorhinal cortex lesion and that of microglia ac-
tivation in the entorhinal cortex area (Fig. 5; two-way
ANOVA with treatment and lesion factors and with re-
peated measures on the last factor: F2,26 = 7.56, P < 0.01).
It was also found that the region of immunoreactive mi-
croglia was larger than that of neuronal cell death (F2,26 =
11.90, P < 0.002), which means that microglia becomes
activated in the areas surrounding the neuronal lesion
that may be considered as a penumbra zone. There was
no signiﬁcant interaction between the treatment–lesion
factors. One-way ANOVA applied separately to neuronal
lesion size and microglia activation area pointed to the
same direction (F2,26 = 7.17, P < 0.01 and F2,26 = 4.71,
P < 0.05 respectively), that is, treatments reduced the
effect of lesion. Vinpocetine reduced the lesion size sig-
niﬁcantly assessed by post hoc Tukey test regarding both
parameters (P < 0.05), while cAVA treatment effect was
94 CNS Neuroscience & Therapeutics 15 (2009) 89–99 c  2009 Blackwell Publishing LtdC. Nyakas et al. Neuroprotective Effects of Vinpocetine
FIRST TRIALS (RM)
Daily sessions
0123456
L
a
t
e
n
c
y
 
i
n
 
s
e
c
o
n
d
s
0
20
40
60
80
100
sham (12)
NMDA (14)
NMDA+Vinp (7)
NMDA+cAVA (7)
MEANS OF 4 TRIALS
Daily sessions
0123456
L
a
t
e
n
c
y
 
i
n
 
s
e
c
o
n
d
s
0
10
20
30
40
50
60
70
sham (12)
NMDA (14)
NMDA+Vinp (7)
NMDA+cAVA (7)
MEANS OF 4 TRIALS
Daily sessions
0123456
L
a
t
e
n
c
y
 
i
n
 
s
e
c
o
n
d
s
0
10
20
30
40
50
60
70
intact (9)
sham (12)
sham+Vinp (6)
sham+cAVA (6)
**
** **
**
*
x xx
## ##
#
# ##
C
B D
FIRST TRIALS (RM)
Daily sessions
0123456
L
a
t
e
n
c
y
 
i
n
 
s
e
c
o
n
d
s
0
20
40
60
80
100
intact (9)
sham (12)
sham+Vinp (6)
sham+cAVA (6)
A
Figure 4 Spatial learning in the Morris water maze after entorhinal cor-
tex lesion and drug treatments (10mg/kg i.p. vinpocetine (Vinp) or cis-
apovincaminic acid (cAVA)). Upper panels (A)a n d( C) show the nonle-
sioned control groups, while panels (B)a n d( D) the NMDA-lesioned ones
and their sham-lesioned controls. Panels (A)a n d( B) present the escape
latencies of the ﬁrst trials at each sessions (reference memory, RM) and
panels (C)a n d( D) the means of four escape latencies performed in each
dailysession.ANOVAanalysesareinthetext.Posthoctestresultsarethe
followings: ∗P<0.05, ∗∗P<0.01 between NMDA versus sham animals; ×
P<0.05,×P<0.01betweenNMDA+VinpandNMDAgroups;#P<0.05,
##P<0.01 between NMDA-cAVA and NMDA groups.
only marginal (P = 0.05) in reducing microglia activa-
tion if the two groups were compared. The decrements in
neuronal lesion size were 23% and 16% after vinpoce-
tine and cAVA, respectively, and those of the microglial
activation area were 27% and 23%, respectively.
Figures 6 and 7 shows representative examples of
the location of neuronal lesion and the extent of im-
munoreactive microglia in the entorhinal cortex-ventral
hippocampus at the level of Bregma –7.6, which was
the level of maximal size of the entorhinal lesion. It can
be observed that the lesion (Fig. 6) and the microglia
invasion (Fig. 7) cover the entire medial entorhinal
cortex and the larger part of the lateral entorhinal cortex,
while the subiculum has also been damaged in the
NMDA-treated animals without drug treatment (Fig. 6).
Cavinton seemed to be more effective to diminish the size
of the lesion compared with cAVA. Microglia activation
was reduced by both compounds. Figure 8 shows with
higher magniﬁcation the survived NeuN positive neurons
(left panel) and the activated microglia cells (right panel).
The border of lesioned and non-lesioned tissue is rather
sharp which allowed to outline the size of neuronal lesion
at low magniﬁcation. The same holds true for microglia
activation although some scattered groups of cells could
also be found (marked by asterisk) around the border of
possibly lesioned and non-lesioned tissue. It might also
CNS Neuroscience & Therapeutics 15 (2009) 89–99 c  2009 Blackwell Publishing Ltd 95Neuroprotective Effects of Vinpocetine C. Nyakas et al.
NMDA NMDA+Vinp NMDA+cAVA
s
u
r
f
a
c
e
 
a
r
e
a
 
(
m
m
2
)
0,0
0,5
1,0
1,5
2,0
2,5
neuronal lesion size 
microglia reaction area
*
*
$
#
(14) (8) (7)
Figure 5 Extent of neuronal lesion and the area of microglia activation
intheentorhinalcortex-hippocampuscomplexfollowingNMDAinjections
at the –7.6 Bregma level. Groups contained 7–14 animals. Vinpocetine
(Vinp) treatment reduced the size of both parameters: ∗ P < 0.05 versus
NMDA-vehicle-treated control group. Treatment with cis-apovincaminic
acid (cAVA) did not diminish signiﬁcantly the neuronal lesion size, while
practically signiﬁcantly reduced the area covered by activated microglia
($P = 0.05 vs. NMDA-vehicle group). Area invaded by activated microglia
extended the size of neuronal lesion but only in case of NMDA-vehicle
group (#P < 0.05).
Figure 6 Size of neuronal lesion in the entorhinal cortex-ventral hip-
pocampus region outlined by the lack of neuron-speciﬁc nuclear pro-
tein(NeuN)immunostainedcells.Photomicrographsarefromrepresenta-
tiveanimalsofsham-lesionedvehicle-treated(A),NMDA-lesionedvehicle-
treated (B), NMDA-lesioned vinpocetine-treated (C), and NMDA-lesioned
cAVA-treated (D) groups. Bar represents 1 mm.
Figure 7 Areas of microglial activation in the entorhinal cortex-ventral
hippocampus region outlined by DC11b immunostaining. Photomicro-
graphs are from representative animals of sham-lesioned vehicle-treated
(A), NMDA-lesioned vehicle-treated (B), NMDA-lesioned vinpocetine-
treated (C), and NMDA-lesioned cAVA-treated (D) groups. Bar represents
1 mm.
be that the scattered activated microglia followed the path
of degenerating axons originated from the lesion core to-
wards the hippocampal projection area.
Discussion
Both vinpocetine and its metabolite cis-apovincaminate
proved to be neuroprotective in an in vivo animal model
of entorhinal cortex lesion with the glutamate analogue
NMDA. The excitotoxic lesion itself markedly impaired
attention in rats measured as the ability to recognize a
novel object or a novel social partner. The lesioned rats
also performed worse in spontaneous alternation in the
Y-maze which reﬂects an attention deﬁcit associated with
impaired working memory. In addition the entorhinal
cortex lesioned animals showed impaired spatial learn-
ing in the Morris water maze including a deﬁcit in refer-
ence memory performance. This entorhinal lesion model,
therefore, mimics all the prominent early cognitive symp-
toms of Alzheimer’s disease. that is, a deﬁcient attention
capability and an impaired episodic memory [17,18].
The lesion in the entorhinal cortex was rather ex-
tensive and accompanied by a massive microglia acti-
vation covering a penumbra-like region around the le-
sion core which hosts the potentially surviving neurons.
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Figure 8 Photomicrographs with higher magniﬁcation allow to identify
the stained neurons and microglia cells. The left panel shows the neuron-
speciﬁc nuclear protein (NeuN) positive neuronal staining, the right panel
the CD11b positive microglia staining. It is noteworthy that the border of
neuronal lesion and the microglia activation is sharp and can be clearly
outlined. In some cases a scattered appearance of activated microglia
could also be observed (asterisks). S, subiculum; ec, external capsule. In
the external capsule no neuronal cell bodies are stained. Bar represents
100 μ.
Vinpocetine and cAVA in a dose of 10mg/kg given shortly
before and continuously for 4 days after the excitotoxic
injection of NMDA attenuated the attention deﬁcit, and
prevented the learning and memory impairment in the
spontaneous alternation and Morris water maze tests.
Vinpocetine signiﬁcantly, and cAVA almost signiﬁcantly,
reduced lesion size, while both drugs reduced microglia
activation.
Cis-apovincaminic acid is the main metabolite of vin-
pocetine in human, thus, it became interesting to com-
pare its action to that of vinpocetine on neurodegener-
ation. In the present study it turned out that cAVA has
almost the same neuroprotective potency as vinpocetine
itself in rats based ﬁrst of all on the behavioral ﬁndings.
Its effectiveness in reducing the size of the neuronal le-
sion and the degree of microglial activation was less pro-
nounced compared with vinpocetine. We may conclude
from the present experiments that vinpocetine and some-
what less potently cAVA rescued part of the entorhinal
neurons from the effects of excitotoxicity and preserved
part of the perforant pathway connection with the hip-
pocampal formation and thereby contributed markedly
to the improved behavioral performance of the lesioned
rats.
Vinpocetine, based on a number of observations dur-
ing the past decades, possesses a neuroprotective type
of action in chronic neurodegenerative diseases that in-
volve a pathological vascular component. In human it
has been shown that vinpocetine increases cerebral blood
ﬂow and metabolism in the penumbra zone in stroke pa-
tients [25]. Animal studies have shown that vinpocetine
reduces neurodegeneration initiated by decreased blood
ﬂow [26–28]. Vinpocetine in clinical studies yielded a
signiﬁcantly better outcome on global cognitive assess-
ments if the memory problems were associated with poor
brain circulation [29]. Both the clinical and the experi-
mental studies focused almost exclusively on those neu-
rodegenerative diseases that are strongly associated with
vascular abnormalities. This is understandable since in
about 80% of dementia cases vascular pathology is a ma-
jor factor that contributes to the diseased state and pro-
motes or helps to exacerbate pathobiochemical processes
characteristic to Alzheimer’s disease [30–32]. These con-
siderations support the notion that the target structures
involved in the pharmacological action of vinpocetine, in-
deed are the endothelial cell, the brain vasculature and
the blood–brain barrier.
The immediate subsequent question in view of the re-
sults of the present study therefore is: which other neu-
ronal and glial target structures may be involved in the
neuroprotective action of vinpocetine? The neurodegen-
eration model used in the present study is principally
based on the in vivo overexcitation of the NMDA glu-
tamate receptor, the subsequent increased intracellular
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Ca2+ concentration and the onset of necrotic and apop-
totic mechanisms [33,34]. Vinpocetine and to a lesser
extent also cAVA diminished glutamatergic excitotoxi-
city and attenuated the size of lesion in the neuronal
population of entorhinal cortex. It has been documented
earlier in vitro that vinpocetine is cellprotective by inter-
fering with the NMDA receptor-Ca2+ channel overexci-
tation [35], which lends further support for the NMDA
receptor as target for drug development in Alzheimer’s
disease [34,36–38]. According to our additional observa-
tion published recently [39] vinpocetine was found to be
neuroprotective in vitro against glutamate toxicity in pri-
mary cortical neuronal culture. Since vinpocetine has a
binding afﬁnity to the peripheral-type benzodiazepine re-
cetors (PBRs, [6]) we investigated whether the neuropro-
tection by vinpocetine can be at least partially due to an
effect on PBRs [39]. The answer in this study was that
during in vitro glutamate excitotoxicity neuronal PBRs are
involved but not likely the primary targets for the neuro-
protective action exerted by vinpocetine.
Vinpocetine and its metabolite cAVA decreased mi-
croglia activation around the lesion in the entorhinal cor-
tex in the present study. While without drug treatment
the area covered by activated microglia signiﬁcantly ex-
ceeded the lesioned area outlined by the loss of NeuN
positive neurons in the NMDA group, treatment with
either vinpocetine or cAVA reduced the extent of mi-
croglia activation relative to the extent of neuronal loss.
In other words in the penumbra region 2 weeks fol-
lowing the NMDA lesion inﬂammatory processes were
still active which were strongly reduced by the drug
treatments.
Microglia activation is present in essentially all condi-
tions where the vitality of the brain tissue is seriously
challenged [40–42]. It is not yet fully understood whether
the microglial activation is neuroprotective or neurode-
structive in nature, but most likely both mechanisms may
occur under speciﬁed time and stage-dependent condi-
tions [43–46]. In this respect it is essential to obtain fur-
ther information on the phase of the inﬂammatory pro-
cess and expression level of life or death signals and their
respective receptor systems [42,47]. Interestingly, acti-
vated microglia synthetizes increased amounts of periph-
eral benzodizepine receptors which act as receptors for
vinpocetine [7,48] and therefore may provide an impor-
tant molecular target for vinpocetine in conditions where
brain tissues is challenged.
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